DealsJun 5, 2026, 07:01 AM
Seres Secures $25M from Nestlé, Restructures Lease to Extend Runway
AI Summary
Seres Therapeutics announced two transactions to strengthen its balance sheet and extend its operating cash runway well into Q1 2027. Nestlé Health Science will pay Seres $25 million in two installments in 2026 to buy out potential future VOWST net sales-based milestones. Additionally, Seres restructured a lease agreement for one of its facilities, significantly reducing leased space, annual cash costs, and long-term lease obligations. The company also anticipates clinical data from an investigator-sponsored SER-155 study later this month.
Key Highlights
- Nestlé Health Science to pay Seres Therapeutics $25 million in two installments (July and October 2026) to buy out future VOWST net sales-based milestones.
- Restructured lease agreement for 101 CambridgePark Drive facility materially reduces leased space, ongoing annual facility cash costs, and long-term lease obligations.
- Transactions are expected to extend Seres' operating cash runway well into the first quarter of 2027.
- As of March 31, 2026, Seres had $29.8 million in cash and cash equivalents.
- Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later this month.
Price Impact
More from MCRB